PRESCRIPTION DRUG MONITORING PROGRAM TRAINING AND TECHNICAL ASSISTANCE CENTER
The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) at the Institute for Intergovernmental Research (IIR) provides a comprehensive array of services, support, resources, & strategies to PDMPs, federal partners and other stakeholders to further the efforts and effectiveness of PDMPs in combating the misuse and diversion of prescription drugs.
News & Events
-
Recent Scheduling of Controlled Substances
Read More October 30, 2026There are three recent announcements from the Drug Enforcement Administration regarding the scheduling of controlled substances:
SCHEDULES OF CONTROLLED SUBSTANCES: PLACEMENT OF CENTANAFADINE IN SCHEDULE III
October 30, 2026. On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemically known as (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in schedule III of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing centanafadine, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible in schedule III of the CSA.The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/30/2026-22208/schedules-of-controlled-substances-placement-of-centanafadine-in-schedule-iii (opens in a new tab).
October 14, 2026. The Administrator of the Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule 7-hydroxymitragynine and mitragynine pseudoindoxyl (including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible) when either substance alone, or their combined amount if both are present, is above a specified threshold, in schedule I of the Controlled Substances Act (CSA). Based on a different threshold provided by the Department of Health and Human Services (HHS) in July of 2025, DEA published a notice of intent to temporarily schedule 7-hydroxymitragynine above that lower threshold on July 7, 2026. Additionally, DEA published a temporary order placing mitragynine pseudoindoxyl without a threshold in schedule I of the CSA on August 26, 2026. On October 8, 2026, HHS sent a letter recommending that DEA place of the CSA 7-hydroxymitragynine and mitragynine pseudoindoxyl in schedule I when either substance alone, or their combined amount if both are present, is above a new specified threshold. Based on the October 8, 2026 letter, DEA is issuing this notice of intent. While the new threshold recommended by HHS would permit certain products to remain in the marketplace without being subject to schedule I controls, neither HHS nor DEA has made a finding that these substances are safe to use at below-threshold levels. When a temporary order is issued, it will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 7-hydroxymitragynine and/or mitragynine pseudoindoxyl above the specified threshold. In a separate document contained in this issue of the Federal Register , DEA is withdrawing the July 7, 2026 notice of intent related to 7-hydroxymitragynine. The August 26, 2026 temporary order placing mitragynine pseudoindoxyl in schedule I of the CSA without a threshold remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first. The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/14/2026-20943/schedules-of-controlled-substances-temporary-placement-of-7--hydroxymitragynine-and-mitragynine (opens in a new tab)
SCHEDULES OF CONTROLLED SUBSTANCES: TEMPORARY PLACEMENT OF MGM-15 AND MGM-16 IN SCHEDULE I
October 14, 2026. The Drug Enforcement Administration (DEA) is issuing this notice of intent to publish a temporary order to schedule two 7-hydroxymitragynine-related substances (MGM-15 and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act (CSA). On August 26, 2026, DEA published a temporary order placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I of the CSA. Today, DEA is providing notice of its intent to publish a new temporary order for MGM-15 and MGM-16 that will maintain the temporary placement of these substances in schedule I of the CSA without change. Separately in this Federal Register , DEA is publishing a notice of intent relating to mitragynine pseudoindoxyl, in response to a letter sent by the Department of Health and Human Services (HHS) dated October 6, 2026. HHS's letter related only to mitragynine pseudoindoxyl. Therefore, DEA is publishing this notice of intent only for the technical and procedural purpose of distinguishing MGM-15 and MGM-16 from mitragynine pseudoindoxyl. When issued, the temporary scheduling order addressing MGM-15 and MGM-16 will continue to impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these two 7-hydroxymitragynine-related substances. The August 26, 2026 temporary order placing these substances in schedule I of the CSA remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first. The Federal Register link can be found here: https://www.federalregister.gov/documents/2026/10/14/2026-20942/schedules-of-controlled-substances-temporary-placement-of-mgm-15-and-mgm-16-in-schedule-i (opens in a new tab)
-
Drugs of Abuse: A Resource Guide, 2026 Edition
Read More September 28, 2026The Drug Enforcement Administration (DEA) released an updated publication, Drugs of Abuse: A Resource Guide, 2026 Edition. Drugs of Abuse delivers clear, scientific information about drugs in a factual, straightforward way. With the information in this guide, parents and caregivers can help their children make smart choices and avoid the consequences of drug abuse. This publication covers topics including the Controlled Substances Act and introduces drug classes including narcotics, stimulants, marijuana/cannabis, inhalants, steroids, and more. More information can be found at https://www.getsmartaboutdrugs.gov (opens in a new tab).
Download the Guide at https://www.getsmartaboutdrugs.gov/sites/default/files/2026-09/Drugs-Abuse-2026.pdf. (opens in a new tab)
-
LAPPA publishes Model Addressing Inhalant Use Act
Read More August 25, 2026The Legislative Analysis and Public Policy Association (LAPPA) is excited to announce publication of the Model Addressing Inhalant Use Act (opens in a new tab). The purpose of this legislation is to: (1) prohibit the sale of certain products containing inhalants to minors; (2) establish additional requirements for the sale of inhalants, including restrictions on advertising and the retail sale of nitrous oxide as well as packaging requirements; (3) establish criminal penalties related to inhalants; and (4) establish education, prevention, and treatment requirements. Regulating inhalants is complicated because many inhalants are common household substances, but doing so is growing increasingly critical as this availability and appearance of “safety” results in adolescents being the largest demographic that uses inhalants. This Model Act seeks to: (1) to implement measures to educate the public, particularly adolescents, on the dangers of inhalant use; and (2) prevent initiation into inhalant use by placing restrictions on purchasing certain products.
Our focus is to improve consistency among PDMPs, facilitate coordination between PDMPs and state and national stakeholders, increase PDMP efficiencies, measure performance and effectiveness, and promote best practices.
REQUEST PDMP TTA
Combat prescription misuse with RxCheck! Facilitate seamless data sharing among states, integrate with EHR systems, and join the nationwide PDMP movement. Developed with BJA support, RxCheck ensures secure data governance, empowering states to own and control their information.
LEARN MORE
